

Mizuki Nishino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7312178/publications.pdf>

Version: 2024-02-01

154
papers

11,727
citations

44069

48
h-index

30922

102
g-index

155
all docs

155
docs citations

155
times ranked

13287
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	9.4	1,108
2	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	27.6	787
3	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	7.1	600
4	Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. <i>New England Journal of Medicine</i> , 2011, 364, 897-906.	27.0	468
5	Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. <i>Clinical Cancer Research</i> , 2013, 19, 3936-3943.	7.0	438
6	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	7.0	393
7	<i>MUC5B</i> Promoter Polymorphism and Interstitial Lung Abnormalities. <i>New England Journal of Medicine</i> , 2013, 368, 2192-2200.	27.0	358
8	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	5.0	340
9	Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 373, 288-290.	27.0	339
10	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 672.	7.4	333
11	Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. <i>American Journal of Roentgenology</i> , 2010, 195, 281-289.	2.2	329
12	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	1.6	288
13	Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1514-1522.	5.6	233
14	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1185-1192.	3.4	227
15	New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non-Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. <i>American Journal of Roentgenology</i> , 2010, 195, W221-W228.	2.2	182
16	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	2.2	169
17	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in <i>STK11</i> - and <i>KEAP1</i> -Mutant Lung Adenocarcinoma Is Affected by <i>KRAS</i> Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
18	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	7.3	147

#	ARTICLE	IF	CITATIONS
19	Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 175-183.	5.6	142
20	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunology Research, 2016, 4, 289-293.	3.4	135
21	Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis and Rheumatology, 2019, 71, 1472-1482.	5.6	129
22	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clinical Cancer Research, 2020, 26, 2615-2625.	7.0	129
23	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 2022, 8, 1160.	7.1	117
24	State of the Art: Response Assessment in Lung Cancer in the Era of Genomic Medicine. Radiology, 2014, 271, 6-27.	7.3	114
25	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clinical Cancer Research, 2017, 23, 4671-4679.	7.0	110
26	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clinical Cancer Research, 2017, 23, 6661-6672.	7.0	110
27	Interstitial Lung Abnormalities and Reduced Exercise Capacity. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 756-762.	5.6	106
28	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268.	2.6	105
29	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 4135-4142.	7.0	95
30	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
31	CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer. Academic Radiology, 2011, 18, 54-62.	2.5	83
32	Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer, 2014, 86, 241-246.	2.0	82
33	Functional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis. Chest, 2014, 146, 41-50.	0.8	78
34	Histopathology of Interstitial Lung Abnormalities in the Context of Lung Nodule Resections. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 955-958.	5.6	78
35	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. , 2014, 2, 17.		77
36	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1402-1413.	5.6	77

#	ARTICLE	IF	CITATIONS
37	Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 204-213.	7.0	73
38	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	7.3	70
39	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	7.0	69
40	Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. , 2019, 7, 112.		69
41	Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2013, 79, 283-288.	2.0	68
42	Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5963-5976.	7.0	63
43	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
44	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management. <i>Cancer Treatment Reviews</i> , 2022, 106, 102378.	7.7	60
45	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. <i>Cancer Immunology Research</i> , 2018, 6, 630-635.	3.4	59
46	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. <i>Lung Cancer</i> , 2018, 123, 60-69.	2.0	58
47	A practical approach to high-resolution CT of diffuse lung disease. <i>European Journal of Radiology</i> , 2014, 83, 6-19.	2.6	57
48	Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. <i>European Radiology</i> , 2016, 26, 15-24.	4.5	57
49	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	3.3	56
50	The <i>MUC5B</i> promoter polymorphism is associated with specific interstitial lung abnormality subtypes. <i>European Respiratory Journal</i> , 2017, 50, 1700537.	6.7	55
51	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 1019-1029.	3.8	55
52	Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. <i>European Journal of Radiology</i> , 2015, 84, 998-1004.	2.6	54
53	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	7.3	53
54	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.8	53

#	ARTICLE	IF	CITATIONS
55	Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021, 48, 656-663.	2.0	52
56	Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. <i>Cancer Imaging</i> , 2012, 12, 225-236.	2.8	50
57	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
58	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 779-792.	1.1	50
59	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
60	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Nonâ€“Small-Cell Lung Cancer Patients Treated with EGFR TKI. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1059-1068.	1.1	48
61	Pulmonary cysts identified on chest CT: are they part of aging change or of clinical significance?. <i>Thorax</i> , 2015, 70, 1156-1162.	5.6	48
62	Anterior mediastinal masses in the Framingham Heart Study: Prevalence and CT image characteristics. <i>European Journal of Radiology Open</i> , 2015, 2, 26-31.	1.6	46
63	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenstrm Macroglobulinemia as a Paradigm. <i>Oncologist</i> , 2015, 20, 1077-1083.	3.7	46
64	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.	2.6	46
65	Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. <i>European Journal of Cancer</i> , 2016, 53, 163-170.	2.8	45
66	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	7.3	45
67	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
68	Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a â€œcommon languageâ€“for the new arena of cancer treatment. , 2016, 4, 30.		44
69	Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 138-141.	5.6	44
70	Paraseptal emphysema: Prevalence and distribution on CT and association with interstitial lung abnormalities. <i>European Journal of Radiology</i> , 2015, 84, 1413-1418.	2.6	42
71	Volumetric tumor growth in advanced nonâ€“small cell lung cancer patients with <i>EGFR</i> mutations during EGFRâ€“tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2013, 119, 3761-3768.	4.1	40
72	RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0. <i>American Journal of Roentgenology</i> , 2013, 201, W64-W71.	2.2	39

#	ARTICLE	IF	CITATIONS
73	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	2.0	39
74	Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436.	2.5	37
75	Difference in diaphragmatic motion during tidal breathing in a standing position between COPD patients and normal subjects: Time-resolved quantitative evaluation using dynamic chest radiography with flat panel detector system (â€œdynamic X-ray phrenicographyâ€). European Journal of Radiology, 2017, 87, 76-82.	2.6	37
76	Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdominal Radiology, 2019, 44, 1917-1927.	2.1	37
77	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) nonâ€“small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
78	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precision Oncology, 2017, 1, 1-12.	3.0	35
79	The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1149-1157.	5.6	35
80	Low dose chest CT protocol (50 mAs) as a routine protocol for comprehensive assessment of intrathoracic abnormality. European Journal of Radiology Open, 2016, 3, 86-94.	1.6	33
81	Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Academic Radiology, 2016, 23, 329-336.	2.5	33
82	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology, 2017, 18, 42.	3.4	33
83	Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. European Journal of Radiology, 2019, 112, 28-36.	2.6	33
84	Time-Resolved Quantitative Analysis of the Diaphragms During Tidal Breathing in a Standing Position Using Dynamic Chest Radiography with a Flat Panel Detector System (â€œDynamic X-Ray Phrenicographyâ€). Academic Radiology, 2017, 24, 393-400.	2.5	32
85	Standard-dose vs. low-dose CT protocols in the evaluation of localized lung lesions: Capability for lesion characterizationâ€”iLEAD study. European Journal of Radiology Open, 2016, 3, 67-73.	1.6	30
86	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Aâ€“Dabrafenib Plus Trametinib. Journal of Thoracic Oncology, 2018, 13, e131-e133.	1.1	30
87	The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. Lung Cancer, 2019, 132, 79-86.	2.0	28
88	Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients. European Radiology, 2016, 26, 286-295.	4.5	24
89	The Associations of Interstitial Lung Abnormalities with Cancer Diagnoses and Mortality. European Respiratory Journal, 2020, 56, 1902154.	6.7	24
90	Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. European Journal of Radiology Open, 2019, 6, 128-131.	1.6	23

#	ARTICLE	IF	CITATIONS
91	Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. <i>European Journal of Radiology</i> , 2019, 113, 59-65.	2.6	22
92	Dynamic Chest X-Ray Using a Flat-Panel Detector System: Technique and Applications. <i>Korean Journal of Radiology</i> , 2021, 22, 634.	3.4	22
93	Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. <i>Journal of Thoracic Oncology</i> , 2021, , .	1.1	21
94	Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. <i>Lung Cancer</i> , 2020, 145, 132-139.	2.0	20
95	Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns. <i>Journal of Clinical Oncology</i> , 2017, 35, 1628-1629.	1.6	19
96	Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. <i>Human Pathology</i> , 2019, 86, 93-101.	2.0	19
97	<scp>PD</scp>-inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. <i>British Journal of Haematology</i> , 2018, 180, 752-755.	2.5	18
98	Volumetric Expiratory HRCT of the Lung: Clinical Applications. <i>Radiologic Clinics of North America</i> , 2010, 48, 177-183.	1.8	16
99	Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. <i>Radiology</i> , 2015, 277, 733-740.	7.3	15
100	Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. <i>Cancer</i> , 2016, 122, 3456-3463.	4.1	15
101	Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib. <i>European Journal of Radiology</i> , 2017, 88, 15-20.	2.6	15
102	Bronchomalacia in Sarcoidosis. <i>Academic Radiology</i> , 2005, 12, 596-601.	2.5	14
103	Thymic Measurements in Pathologically Proven Normal Thymus and Thymic Hyperplasia. <i>Academic Radiology</i> , 2014, 21, 733-742.	2.5	14
104	Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2019, 34, 103-115.	1.5	14
105	Imaging of Histiocytosis in the Era of Genomic Medicine. <i>Radiographics</i> , 2019, 39, 95-114.	3.3	14
106	Projected lung areas using dynamic X-ray (DXR). <i>European Journal of Radiology Open</i> , 2020, 7, 100263.	1.6	14
107	Difference in the craniocaudal gradient of the maximum pixel value change rate between chronic obstructive pulmonary disease patients and normal subjects using sub-mGy dynamic chest radiography with a flat panel detector system. <i>European Journal of Radiology</i> , 2017, 92, 37-44.	2.6	13
108	Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. <i>European Journal of Radiology</i> , 2020, 132, 109275.	2.6	13

#	ARTICLE	IF	CITATIONS
109	Traction Bronchiectasis/Bronchiolectasis on CT Scans in Relationship to Clinical Outcomes and Mortality: The COPD Gene Study. <i>Radiology</i> , 2022, 304, 694-701.	7.3	13
110	Case 155: Lane-Hamilton Syndrome. <i>Radiology</i> , 2010, 254, 985-988.	7.3	12
111	Pseudoprogression and Measurement Variability. <i>Journal of Clinical Oncology</i> , 2016, 34, 3480-3481.	1.6	12
112	Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features. <i>Occupational and Environmental Medicine</i> , 2017, 74, 756-761.	2.8	11
113	Perinodular Radiomic Features to Assess Nodule Microenvironment: Does It Help to Distinguish Malignant versus Benign Lung Nodules?. <i>Radiology</i> , 2019, 290, 793-795.	7.3	10
114	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
115	Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. <i>European Journal of Radiology</i> , 2018, 109, 68-76.	2.6	8
116	Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers. <i>Chest</i> , 2022, 161, 999-1010.	0.8	8
117	Interstitial lung abnormalities are associated with decreased mean telomere length. <i>European Respiratory Journal</i> , 2022, 60, 2101814.	6.7	8
118	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. <i>Journal of Thoracic Imaging</i> , 2020, 35, 101-107.	1.5	7
119	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	2.2	7
120	Management of Pulmonary Nodules in Oncologic Patients: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 1423-1431.	2.2	7
121	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15113-e15113.	1.6	7
122	Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma. <i>JAMA Oncology</i> , 2017, 3, 703.	7.1	5
123	M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. <i>Oncologist</i> , 2019, 24, e749-e754.	3.7	5
124	Volumetric Expiratory HRCT of the Lung: Clinical Applications. <i>Thoracic Surgery Clinics</i> , 2010, 20, 121-127.	1.0	4
125	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. <i>European Journal of Radiology Open</i> , 2020, 7, 100210.	1.6	4
126	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	3.0	4

#	ARTICLE	IF	CITATIONS
127	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9082-9082.	1.6	4
128	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score $\geq 90\%$.. Journal of Clinical Oncology, 2019, 37, 9111-9111.	1.6	4
129	Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non-Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2021, 5, 1603-1610.	3.0	4
130	Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC. JTO Clinical and Research Reports, 2020, 1, 100072.	1.1	4
131	Radiomics to Predict Invasiveness of Part-Solid Adenocarcinoma of the Lung. Radiology, 2020, 297, 459-461.	7.3	3
132	Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) $\geq 90\%$ treated with first-line pembrolizumab.. Journal of Clinical Oncology, 2022, 40, 9043-9043.	1.6	3
133	Using CT to Evaluate Visceral Pleural Invasion: Caution Is Advised. Radiology, 2019, 292, 750-751.	7.3	2
134	Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer, 2019, 127, 168.	2.0	2
135	CT Volumetry for Lung-RADS Classification of Solid Nodules. Radiology, 2020, 297, 685-686.	7.3	2
136	BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma. JTO Clinical and Research Reports, 2021, 2, 100127.	1.1	2
137	DNMT3A mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.. Journal of Clinical Oncology, 2021, 39, 9113-9113.	1.6	2
138	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. Journal of Clinical Oncology, 2021, 39, 9121-9121.	1.6	2
139	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9077-9077.	1.6	2
140	Reply to "Usefulness of CT in Differentiating Lymphoid Thymic Hyperplasia From True Thymic Hyperplasia: Added Value of Thymic Measurements and CT Attenuation". American Journal of Roentgenology, 2015, 204, W115-W115.	2.2	1
141	Immune-related tumor response dynamics in melanoma patients (pts) treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions.. Journal of Clinical Oncology, 2017, 35, 9521-9521.	1.6	1
142	Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9021-9021.	1.6	1
143	Risk of Bias and Heterogeneity"Reply. JAMA Oncology, 2017, 3, 858.	7.1	0
144	Diagnosis Please Certificates of Recognition Awarded to Three Individuals and to International and North American Radiology Resident Groups. Radiology, 2019, 293, 241-244.	7.3	0

#	ARTICLE	IF	CITATIONS
145	Diagnosis Please Certificates of Recognition Awarded to Five Individuals and to International and North American Radiology Resident Groups. <i>Radiology</i> , 2020, 297, 247-250.	7.3	0
146	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9119-9119.	1.6	0
147	Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9103-9103.	1.6	0
148	Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Imaging</i> , 2021, Publish Ahead of Print, .	1.5	0
149	Diagnosis Please Certificates of Recognition Awarded to Four Individuals and to International and North American Radiology Resident Groups. <i>Radiology</i> , 2021, 301, 497-501.	7.3	0
150	Drug Toxicity, Approach to Cancer as a Systemic Disease, and Imaging Modality-Specific Considerations. <i>Medical Radiology</i> , 2020, , 31-43.	0.1	0
151	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9568-9568.	1.6	0
152	Response Evaluations for Precision Cancer Therapy and Immunotherapy. <i>Medical Radiology</i> , 2020, , 15-27.	0.1	0
153	Therapy Response Imaging in Thoracic Malignancy. <i>Medical Radiology</i> , 2020, , 79-97.	0.1	0
154	Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma. <i>Radiology</i> , 2022, , 213015.	7.3	0